Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 9/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2331650 | 0.85 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3IGF1R | |
| SCHEMBL2324213 | 0.77 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3ROCK2 | |
| SCHEMBL2329659 | 0.75 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3IGF1R | |
| SCHEMBL2327464 | 0.75 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2329771 | 0.74 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3IGF1R | |
| SCHEMBL3317491 | 0.74 | IGF1R (0.43) | IGF1RKCNH2ACVR1 | |
| SCHEMBL5655721 | 0.74 | CHRNB2 (0.72) | CHRNB2CHRNA4ACVR1 | |
| SCHEMBL2322554 | 0.73 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3IGF1R | |
| SCHEMBL2327327 | 0.72 | CHRNB4 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3ROCK2 | |
| SCHEMBL2326203 | 0.72 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-10-20 | — | — | US | claimed |
| EP-2356125-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Targacept, Inc. (US) | 2011-08-17 | — | — | EP | claimed |
| WO-2010002971-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2356125-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Targacept, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010002971-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA5, CHRNA2, CHRNB2 | CHRNB2 3/4885CHRNA4 9/4885CHRNB4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.